Investment Rating - The industry rating is "Recommended" [6] Core Insights - Nike's FY26Q2 performance showed regional revenue changes: North America +9%, EMEA -1%, Greater China -16%, APLA -4%, with Greater China significantly dragging down overall performance due to weak foot traffic, poor new product sell-through rates, and aging inventory [3][16] - The Central Economic Work Conference emphasized expanding domestic demand as a priority, focusing on enhancing the supply of quality goods and services, and promoting investment recovery [4][17] - The report suggests a cautious outlook for FY26Q3, with expected revenue declines in certain regions and a focus on the "Win Now" strategy in Greater China [3][16] Summary by Sections 1. Weekly Insights - Nike's performance in FY26Q2 highlighted a significant decline in Greater China, attributed to weak customer traffic and inventory issues [3][16] - The company is implementing pilot store projects in Greater China to improve sales performance [3][16] 2. Market Review - The SW textile and apparel sector increased by 2.42%, outperforming the Shanghai Composite Index by 1.32% [19] - Key stocks with the highest gains included Yimin Group and Huamao Co., while stocks like Hason and *ST Bosen faced significant declines [19][24] 3. Industry Data Tracking 3.1 Raw Material Data - The China cotton price index rose by 2.96% year-to-date, while wool prices increased by 29.52% since the beginning of the year [34][40] - The USDA forecasts a 0.34% increase in total cotton production for 2025, with a slight decline in demand [46] 3.2 Export Data - Textile and apparel exports from January to November 2025 decreased by 1.9% year-on-year, with a notable decline in apparel exports [54] - The export value of tarpaulins and canopies fell by 21.18% in October 2025 [59] 4. Industry News - Notable developments include the opening of Descente's flagship store in Beijing and the re-entry of Spanish fast fashion brands into the Chinese market [10][4]

证券研究报告|宏观跟踪周报 [Table_Date] 2025 年 12 月 20 日 [Table_Title] 年末存单利率或迎下行拐点 [Table_Title2] 流动性跟踪 [Table_Summary] ►概况：税期，资金面继续平稳 12月 15-19日，税期资金面依旧维持低位运行。周内来看，15日为税期首日， 2000 亿元 6M 买断式逆回购净投放落地，同时为保持资金利率稳定，央行在短期资 金投放上维持常规续作安排。尽管如此，税期期间隔夜利率 R001 始终维持在 1.34- 1.35%水平，7 天资金 R007 也基本稳定于 1.50%附近。 税期之后，跨年因素接替成为影响资金面的主要逻辑。18 日起拆借 14 天资金 可跨年，除了常规续作 7 天逆回购以外，央行连续两日额外投放 1000 亿元 14 天逆 回购，呵护跨年资金面，进一步推动了资金宽松预期。受此影响，18-19日 R014仅 小幅上行 7bp 至 1.62%，跨年压力整体可控。与此同时，隔夜与 7 天资金利率仍延 续此前稳态，日均波动不足 1bp，R001、R007 分别收于 1.35%、1.51%。 ►展望：年末存单利率或迎 ...

李立峰 SAC NO:S1120520090003 证券研究报告 最新A股、港股、美股估值怎么看？ ——估值周报（1215-1219） 冯逸华 SAC NO:S1120523070007 2025年12月20日 请仔细阅读在本报告尾部的重要法律声明 全球主要指数估值总览 资料来源： wind ，华西证券研究所 2 图表1：全球主要指数PE(TTM) 0 20 40 60 80 100 120 140 160 上证指数 创业板指 恒生指数 恒生科技 标普500 纳斯达克指数 道琼斯工业指数 日经225 德国DAX 中位数 最大值 最小值 现值 A股 港股 美股 日股 德股 注：自2010年1月起，截至2025年12月19日 目录 风险提示 3 一、A股市场估值水平 二、A股行业估值水平 三、机构重仓个股估值水平 四、港股市场估值水平 五、港股行业与个股估值水平 六、美股市场估值水平 七、中概股估值、中美银行股估值比较 1.1 A股绝对估值变化 4 图表2、3：A股整体PE(TTM)、A股剔除金融和石油石化PE(TTM，剔除负值) 资料来源： wind ，华西证券研究所 4 17.15 5 10 15 20 25 ...

证券研究报告|固收点评报告 [Table_Date] 2025 年 12 月 20 日 [Table_Title] 新房年末冲量 [Table_Title2] able_Summary] 地产周速达 1）周度： 同比降幅持续收敛，二手房修复弹性更强。本周 38 城新房成交同比下滑 31%，降幅较上周收窄 2 个百分 点，已连续十二周负增长；15 城二手房成交同比降幅则大幅收敛 11 个百分点至 23%，已连续十周负增长，二 手房的边际修复速度快于新房。 2）月度： 统计局数据显示，11 月地产销量环比修复好于 2021-2023 年同期，但"以价换量"特征显著。同比来 看，受去年"924"后的高基数压制，11 月商品房销售面积、销售额同比分别下滑 17.3%和 25.1%。与 10 月 增速相比，销售面积降幅收窄 1.5pct，而销售额降幅反而扩大 0.8pct，呈现显著的"量价背离"。环比维度 上，11 月销售面积增长 9.3%，虽弱于 2015-2019 年同期，但强于 2021-2023 年同期均值（+8.0%）及去年同 期（+7.1%），显示市场活跃度边际修复。不过 11 月销售额环比仅微增 2.3% ...

Group 1: Global Market Overview - The Bank of Japan announced an interest rate hike, leading to increased volatility in global markets[1] - The S&P 500 Shiller PE ratio remains high at 40.15, indicating potential for further correction in U.S. tech stocks[1] - Major European indices like DAX and CAC40 are expected to experience further fluctuations due to high price-to-book ratios[1] Group 2: U.S. Market Performance - The S&P 500 index increased by 0.1%, while the Nasdaq rose by 0.48% this week[2] - The Dow Jones Industrial Average fell by 0.67% during the same period[2] - The technology sector remains overvalued, with the TAMAMA technology index PE at 36.54 and the Philadelphia Semiconductor index at 42.28[1] Group 3: Asian Market Insights - The Nikkei 225 index saw a significant decline of 2.61% this week, with expectations of further corrections due to high valuations[2] - The Hang Seng Index and related indices experienced declines of 1.1% to 2.39% this week, indicating market pressure[2] - Emerging markets like the Korean Composite Index and others are likely to face volatility due to economic fundamentals and valuation concerns[1] Group 4: Economic Indicators - Japan's CPI growth rate for November was 2.9%, down from 3% previously, indicating a potential easing of inflationary pressures[4] - The U.S. and Japan's monetary policies are diverging, contributing to market uncertainties[1] - Global geopolitical risks and unexpected economic growth could pose additional threats to market stability[5]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [4][7]. Core Insights - The company, Yutong Optical, is a leading global provider of optical solutions, particularly in the security lens market, where it has maintained the largest market share for ten consecutive years [1][2]. - The company is expanding into the automotive optical market and has established a solid competitive position through acquisitions and technological advancements [1][2]. - Yutong Optical is also diversifying into new consumption sectors, including machine vision and AR/VR lenses, which are expected to drive future growth [1][3]. Summary by Relevant Sections Company Overview - Yutong Optical was founded in 2011 and went public in September 2019. It is the largest supplier of security lenses globally, with a strong market position in the security sector [1][13]. - The company has established a wholly-owned subsidiary for automotive vision and acquired JiuZhou Optical to enhance its competitiveness in the automotive lens market [1][2]. Business Layout - The company has developed a diversified business model centered around security, automotive optics, smart home applications, machine vision, and emerging optical applications [20][24]. - The product matrix includes a wide range of security lenses that cater to various applications, from consumer monitoring to high-end industry surveillance [2][54]. Financial Analysis - Revenue projections for 2025-2027 are estimated at 36.52 billion, 46.62 billion, and 58.35 billion yuan, representing year-on-year growth rates of 33.1%, 27.7%, and 25.2% respectively [4][8]. - Net profit forecasts for the same period are 2.83 billion, 4.85 billion, and 7.00 billion yuan, with growth rates of 54.1%, 71.3%, and 44.5% respectively [4][8]. - The company's gross margin is expected to improve, reflecting a focus on product structure optimization and increased R&D investment [28]. Security Lens Market - Yutong Optical's security lens segment is characterized by a comprehensive product range that meets diverse market needs, supported by long-term partnerships with major security firms [2][54]. - The company is actively expanding its overseas market presence, with a notable increase in international revenue [57]. Automotive Optical Market - The automotive optical segment is positioned for growth, with the company supplying major automotive manufacturers and developing a complete product matrix for smart driving systems [2][58]. - The demand for automotive cameras is expected to rise as smart driving technology becomes more prevalent [58]. Emerging Business Areas - The company is exploring new consumption markets, including sports cameras and AI glasses, which are anticipated to contribute significantly to revenue growth [3][19]. - Collaborations with leading technology firms in these sectors are expected to enhance product delivery and market penetration [3][42].

Investment Rating - The investment rating for the company is "Buy" [4] Core Insights - The company's core products have successfully been included in the 2025 National Medical Insurance Drug List, which is expected to drive sales growth [1][3] - The clinical data for the PD-1/VEGF bispecific antibody RC148 shows promising efficacy and safety in treating non-small cell lung cancer, indicating a significant clinical advantage [2][4] - The management team is experienced, and the company has a strong R&D capability, with a stable pipeline of clinical indications [8] Summary by Sections Event 1 - Two innovative drugs from the company have been successfully included in the 2025 National Medical Insurance Drug List, with one new indication for 泰爱® (Tai'ai) and three renewed indications for both 泰爱® and 爱地希® (Aidiqi) [1] Event 2 - The clinical research data for RC148 in treating non-small cell lung cancer has been disclosed, showing outstanding clinical efficacy and manageable safety [2] Clinical Data - The clinical trial results for RC148 indicate an objective response rate (ORR) of 61.9% for monotherapy and 66.7% for combination therapy, with a disease control rate (DCR) of 100% and 95.2% respectively [4] Financial Projections - Revenue projections for 2025-2027 are adjusted to 27.52 billion, 33.85 billion, and 44.13 billion yuan, reflecting year-on-year growth rates of 60.95%, 22.97%, and 30.40% respectively [8] - The net profit for the same period is projected to improve significantly, with estimates of -7.63 billion, -3.16 billion, and 3.84 billion yuan [8]

Investment Rating - The industry investment rating is "Recommended" [1] Core Views - The merger of CICC, Dongxing Securities, and Xinda Securities is expected to enhance competitive advantages through regional expansion, customer resource integration, and business diversification [2] - The transaction involves a share swap where CICC will issue approximately 3.096 billion A-shares to the shareholders of Dongxing and Xinda, with a total transaction value of about 114.3 billion yuan, reflecting a 14% premium over the market value prior to the suspension [3][4] - Post-merger, CICC's total assets, revenue, and net profit are projected to reach 1,009.6 billion yuan, 27.4 billion yuan, and 9.5 billion yuan respectively, improving its rankings in the industry [7] Summary by Sections Transaction Overview - The merger involves the integration of Dongxing Securities and Xinda Securities into CICC, leveraging their regional strengths and customer bases [2] - The share swap ratio is set at 1:0.4373 for Dongxing and 1:0.5188 for Xinda, with the total transaction amounting to approximately 114.3 billion yuan [4] Financial Metrics - The swap prices are determined based on the average stock prices over the 20 trading days prior to the pricing date, with CICC's net asset value at 115.5 billion yuan, Dongxing at 29.6 billion yuan, and Xinda at 26.4 billion yuan [3] - The overall transaction price-to-book ratio is 2.29 times, indicating a favorable valuation for the merger [4] Shareholder Structure Changes - After the merger, Central Huijin will hold approximately 1.936 billion shares of CICC, representing 24.44% of the total shares, maintaining its status as the controlling shareholder [5] - The shareholding structure will see significant changes, with the public shareholders' proportion increasing post-merger [6] Strategic Advantages - The merger will expand CICC's network from 245 to 436 branches and increase retail clients from 9.72 million to 14 million, enhancing its market presence [7] - CICC aims to utilize the strengths of the acquired companies in asset management and investment opportunities, particularly in non-performing assets and innovative financial products [7] Market Outlook - The consolidation in the securities industry is expected to stimulate investor interest, with the overall industry price-to-book ratio currently at 1.38 times, indicating potential for strategic investment opportunities [9]

Group 1 - Controlled nuclear fusion is considered a future ideal energy source due to its high energy output compared to nuclear fission, with 1 gram of deuterium-tritium fusion fuel releasing energy equivalent to 11.2 tons of standard coal, which is about four times that of 1 gram of uranium-235 fission [12][13] - The deuterium-tritium reaction is the mainstream application in nuclear fusion, offering advantages such as feasible fuel acquisition, high technical feasibility, and significant energy gain, making it the most viable path for achieving net energy gain and commercial power generation [18][19] - Magnetic confinement is recognized as the most promising method for achieving large-scale controlled nuclear fusion, with superconducting technology being key to future device miniaturization and cost reduction [1][25] Group 2 - The global demand for electricity is increasing, driven by data centers, which currently consume about 415 TWh and are expected to double to approximately 945 TWh by 2030, making controlled nuclear fusion an ideal energy solution [2][3] - The progress in controlled nuclear fusion has shifted from "can it ignite" to "can it operate long-term, stably, and economically," with significant advancements in devices like EAST and ITER laying the groundwork for commercial viability [2][3] - Major domestic projects in China, such as EAST and BEST, are expected to see capital expenditures exceeding 92 billion yuan over the next five years, benefiting local companies involved in the supply chain [4][6] Group 3 - The manufacturing value of midstream equipment in the tokamak devices is significant, with over 50% of the value chain attributed to midstream equipment, including key components like vacuum chambers and superconducting magnets [3][6] - Domestic companies are expected to benefit from the nuclear fusion sector, with investments in upstream materials and midstream equipment manufacturing, including companies like Western Superconducting, Antai Technology, and China Nuclear Power [6][4] - The capital expenditure in China's controlled nuclear fusion sector is projected to maintain around 92 billion yuan from 2026 to 2030, with annual investments exceeding 10 billion yuan [6][4]

Investment Rating - The investment rating for the company is "Buy" [4] Core Insights - The company has successfully included three core products in the national medical insurance directory, enhancing accessibility for patients [1][3] - A collaboration with Crescent Biopharma aims to develop and commercialize new cancer treatment methods, focusing on ADC and dual-specific antibodies [2][7] - The company is expected to see significant revenue growth due to the successful inclusion of its products in the national insurance scheme and its strong R&D capabilities [8] Summary by Sections Event 1 - The company's three core products, including ADC Sacituzumab Tirumotecan, have been included in the national medical insurance directory, with two indications for the ADC product [1] - This inclusion is expected to improve patient access and benefit a larger clinical population [3] Event 2 - The partnership with Crescent Biopharma will facilitate the development of SKB105 and CR-001, targeting ITGB6 and PD-1xVEGF respectively [2] - The collaboration includes rights for independent development of combination therapies, enhancing the company's pipeline [2][7] Analyst Commentary - The successful inclusion of the ADC product in the insurance directory showcases its clinical potential and market viability [3] - The company is actively expanding its international clinical collaborations, which is expected to bolster cash flow and explore new treatment combinations [7] Financial Projections - Revenue forecasts for 2025-2027 are adjusted to 21.75 billion, 29.12 billion, and 49.23 billion respectively, with year-on-year growth rates of 12.52%, 33.89%, and 69.06% [8][10] - The company is projected to achieve profitability by 2027, with a net profit of 790.85 million [10][12]